FDA to Meet on Long-Lasting Zyprexa

WASHINGTON -The Food and Drug Administration has scheduled a meeting next month to review the safety and effectiveness of a long-acting version of Eli Lilly & Co.'s schizophrenia drug.
MORE ON THIS TOPIC